PL3325623T3 - Zastosowanie skojarzenia cząsteczki dbait i inhibitorów parp do leczenia nowotworu - Google Patents
Zastosowanie skojarzenia cząsteczki dbait i inhibitorów parp do leczenia nowotworuInfo
- Publication number
- PL3325623T3 PL3325623T3 PL16744699T PL16744699T PL3325623T3 PL 3325623 T3 PL3325623 T3 PL 3325623T3 PL 16744699 T PL16744699 T PL 16744699T PL 16744699 T PL16744699 T PL 16744699T PL 3325623 T3 PL3325623 T3 PL 3325623T3
- Authority
- PL
- Poland
- Prior art keywords
- combination
- treat cancer
- parp inhibitors
- dbait molecule
- dbait
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306201 | 2015-07-23 | ||
| EP16166674 | 2016-04-22 | ||
| EP16744699.6A EP3325623B3 (en) | 2015-07-23 | 2016-07-22 | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| PCT/EP2016/067479 WO2017013237A1 (en) | 2015-07-23 | 2016-07-22 | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL3325623T3 true PL3325623T3 (pl) | 2019-12-31 |
| PL3325623T6 PL3325623T6 (pl) | 2022-05-30 |
Family
ID=56551383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16744699T PL3325623T6 (pl) | 2015-07-23 | 2016-07-22 | Zastosowanie skojarzenia cząsteczki dbait i inhibitorów parp do leczenia nowotworu |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10563197B2 (pl) |
| EP (2) | EP3325623B3 (pl) |
| JP (1) | JP6457696B2 (pl) |
| KR (1) | KR101896567B1 (pl) |
| CN (1) | CN108138177B9 (pl) |
| AU (1) | AU2016296905B2 (pl) |
| CA (1) | CA2993270C (pl) |
| DK (2) | DK3325623T6 (pl) |
| ES (2) | ES2879434T3 (pl) |
| HK (1) | HK1248281B (pl) |
| HU (1) | HUE045916T2 (pl) |
| IL (1) | IL256799A (pl) |
| LT (1) | LT3325623T (pl) |
| PL (1) | PL3325623T6 (pl) |
| PT (1) | PT3325623T (pl) |
| SI (1) | SI3325623T1 (pl) |
| WO (1) | WO2017013237A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709076D0 (en) * | 2017-06-07 | 2017-07-19 | Inst Of Cancer Research: Royal Cancer Hospital | Parp inhibitors for use in methods of treating cancer |
| EP3461488A1 (en) * | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| JP7534218B2 (ja) * | 2018-03-13 | 2024-08-14 | ヴァレリオ・セラピューティクス | がんの治療における獲得耐性に対抗するｄｂａｉｔ分子 |
| AU2019408408A1 (en) * | 2018-12-21 | 2021-06-03 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| AU2020242287A1 (en) * | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| PH12021552205A1 (en) * | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| WO2022058338A1 (en) * | 2020-09-15 | 2022-03-24 | Oncoinvent As | Preparations of radium-224 and progenies for use in radionuclide therapy in combination with dna repair inhibitors |
| CN114478534B (zh) * | 2020-10-24 | 2025-08-05 | 杭州中美华东制药有限公司 | 具有抗肿瘤活性的嵌合分子及其制备方法和应用 |
| EP4448761A1 (en) | 2021-12-16 | 2024-10-23 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI903966A7 (fi) | 1989-08-11 | 1991-02-12 | Ici Plc | Typpiyhdisteitä |
| IE903911A1 (en) | 1989-11-20 | 1991-05-22 | Ici Plc | Diazine derivatives |
| WO1991014696A1 (en) | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
| EP0453210A3 (en) | 1990-04-19 | 1993-01-13 | Imperial Chemical Industries Plc | Pyridine derivatives |
| US5843643A (en) | 1992-02-21 | 1998-12-01 | Ratner; Paul L. | Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid |
| US5646042A (en) | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| DE4418965A1 (de) | 1994-05-31 | 1995-12-07 | Boehringer Ingelheim Int | Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen |
| JP2002514892A (ja) | 1995-06-08 | 2002-05-21 | コブラ セラピューティクス リミテッド | 遺伝子治療における合成ウイルス様粒子の使用 |
| AUPN741696A0 (en) | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
| WO1999013915A1 (en) | 1997-09-15 | 1999-03-25 | Genetic Immunity, Llc. | Method of delivering genes to antigen presenting cells of the skin |
| US7635722B1 (en) | 1998-07-27 | 2009-12-22 | Saint Jude Pharmaceuticals, Inc. | Chemical induced intracellular hyperthermia |
| TR200102005T2 (tr) | 1999-01-11 | 2001-12-21 | Agouron Pharmaceuticals,Inc. | Poli(adp-ribaz) polimerazların trisiklik inhibitörleri. |
| AU2004200A (en) | 1999-01-14 | 2000-08-01 | Meiji Seika Kaisha Ltd. | Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives |
| US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| EP1183259A2 (de) | 1999-09-28 | 2002-03-06 | Basf Aktiengesellschaft | Azepinoindol-derivate, deren herstellung und anwendung |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US6444676B1 (en) | 1999-12-20 | 2002-09-03 | Iok-Hou Pang | Use of PARP inhibitors in the treatment of glaucoma |
| ATE372337T1 (de) | 2000-02-01 | 2007-09-15 | Abbott Gmbh & Co Kg | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
| JPWO2001079184A1 (ja) | 2000-04-18 | 2004-03-18 | 住友製薬株式会社 | 置換ピペラジン類 |
| US20060276497A1 (en) | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
| US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| AU2001264595A1 (en) | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2001275085A1 (en) | 2000-06-01 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Methods, compounds and compositions for treating gout |
| GB0017508D0 (en) | 2000-07-17 | 2000-08-30 | Novartis Ag | Antimicrobials |
| US6903101B1 (en) | 2000-08-10 | 2005-06-07 | Bayer Pharmaceuticals Corporation | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| KR100804564B1 (ko) | 2000-10-30 | 2008-02-20 | 쿠도스 파마슈티칼스 리미티드 | 프탈라지논 유도체 |
| ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| WO2002044157A2 (en) | 2000-12-01 | 2002-06-06 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
| EP1339402B1 (en) | 2000-12-01 | 2010-08-25 | Eisai Inc. | Azaphenanthridone derivatives and their use as parp inhibitors |
| JPWO2002068407A1 (ja) | 2001-02-28 | 2004-06-24 | 山之内製薬株式会社 | ベンゾイミダゾール化合物 |
| DE60231868D1 (de) | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| JP3935363B2 (ja) | 2001-06-26 | 2007-06-20 | サカタインクス株式会社 | 水性顔料分散体の製造方法およびその方法から得られる水性顔料分散体 |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| WO2003014121A1 (en) | 2001-08-07 | 2003-02-20 | Guilford Pharmaceuticals Inc. | Compounds, derivatives, compositions, preparation and uses |
| EP1423120A4 (en) | 2001-08-15 | 2005-12-28 | Icos Corp | 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF |
| US20030096833A1 (en) | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
| AU2002358650A1 (en) | 2001-12-14 | 2003-06-30 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
| WO2003057145A2 (en) | 2001-12-31 | 2003-07-17 | Guilford Pharmaceuticals Inc. | SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES |
| US7026311B2 (en) | 2002-01-10 | 2006-04-11 | Abbott Gmbh & Co., Kg | Dibenzodiazepine derivatives, their preparation and use |
| JPWO2004043959A1 (ja) | 2002-11-12 | 2006-03-09 | 持田製薬株式会社 | 新規ｐａｒｐ阻害剤 |
| WO2004048339A1 (ja) | 2002-11-22 | 2004-06-10 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| KR101146806B1 (ko) | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| BRPI0408996A (pt) | 2003-03-31 | 2006-03-28 | Pfizer | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
| HU227948B1 (en) | 2003-04-30 | 2012-07-30 | Pecsi Tudomanyegyetem | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme |
| ES2396334T3 (es) | 2003-05-28 | 2013-02-20 | Eisai Inc. | Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP |
| WO2004108723A1 (en) | 2003-06-04 | 2004-12-16 | Altana Pharma Ag | 4,5-dihydro-imidazo[4,5,1-ii]quinolin-6-ones as parp inhibitors |
| PL1660095T3 (pl) | 2003-07-25 | 2010-07-30 | Cancer Research Tech Ltd | Tricykliczne inhibitory PARP |
| EP1663202A1 (en) | 2003-09-04 | 2006-06-07 | Aventis Pharmaceuticals, Inc. | Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp) |
| WO2005023800A1 (en) | 2003-09-04 | 2005-03-17 | Warner-Lambert Company Llc | Halo substituted benzo`b! thiophenes with pi3k inhibitory activity as therapeutic agents |
| EP1526177A1 (en) | 2003-10-24 | 2005-04-27 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
| US7476729B2 (en) | 2003-10-24 | 2009-01-13 | Institut Curie | Dbait and uses thereof |
| KR101118582B1 (ko) | 2003-11-20 | 2012-02-27 | 얀센 파마슈티카 엔.브이. | 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논 |
| MXPA06005686A (es) | 2003-11-20 | 2006-08-17 | Janssen Pharmaceutica Nv | 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa. |
| CA2546657C (en) | 2003-12-05 | 2013-05-14 | Janssen Pharmaceutica N.V. | 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| JP4948178B2 (ja) | 2003-12-10 | 2012-06-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤としての置換６−シクロヘキシルアルキル置換２−キノリノンおよび２−キノキサリノン |
| DE202004003061U1 (de) | 2004-02-25 | 2005-07-14 | Kronospan Technical Company Ltd., Engomi | Dekorpapier mit elektrisch geladenen Fasern |
| PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| WO2005108400A1 (ja) | 2004-05-11 | 2005-11-17 | Mochida Pharmaceutical Co. Ltd. | 二環系へテロ環で置換されたピリドキナゾリン誘導体 |
| EP1750714A1 (en) | 2004-05-13 | 2007-02-14 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| DE102004028973A1 (de) | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| CN1980674B (zh) | 2004-06-30 | 2011-05-25 | 詹森药业有限公司 | 作为parp抑制剂的2,3-二氮杂萘衍生物 |
| ES2415771T3 (es) | 2004-06-30 | 2013-07-26 | Janssen Pharmaceutica N.V. | Derivados de quinazolina como inhibidores de PARP |
| EA012837B1 (ru) | 2004-06-30 | 2009-12-30 | Янссен Фармацевтика Н.В. | Производные хиназолинона в качестве ингибиторов parp |
| CA2573673A1 (en) | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
| WO2007040469A2 (en) | 2005-09-15 | 2007-04-12 | Kosak Ken M | Chloroquine coupled compositions and methods for their synthesis |
| KR100876520B1 (ko) | 2004-09-22 | 2008-12-31 | 화이자 인코포레이티드 | 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법 |
| EP1793830A2 (en) | 2004-09-22 | 2007-06-13 | Pfizer, Inc. | Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor |
| MX2007002461A (es) | 2004-09-22 | 2008-03-13 | Pfizer | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona. |
| DE102004050196A1 (de) | 2004-10-15 | 2006-04-20 | Sanofi-Aventis Deutschland Gmbh | Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| US20060128777A1 (en) | 2004-11-05 | 2006-06-15 | Bendall Heather H | Cancer treatments |
| MX2007007032A (es) | 2004-12-17 | 2007-07-04 | Amgen Inc | Compuestos de aminopirimidina y metodos de uso. |
| WO2006078503A2 (en) | 2005-01-07 | 2006-07-27 | Arqule, Inc. | Compositions for modulation of parp and methods for screening for same |
| CA2595290C (en) | 2005-01-19 | 2013-06-25 | Mgi Gp, Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp |
| WO2006110683A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| CN101233121A (zh) | 2005-06-10 | 2008-07-30 | 彼帕科学公司 | Parp调节剂和癌症的治疗 |
| WO2006137510A1 (ja) | 2005-06-24 | 2006-12-28 | Ono Pharmaceutical Co., Ltd. | 脳血管障害時における出血低減剤 |
| CN101242822B (zh) | 2005-07-18 | 2011-08-24 | 彼帕科学公司 | 治疗卵巢癌的药物 |
| CN101316834A (zh) | 2005-09-29 | 2008-12-03 | 艾博特公司 | 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂 |
| AU2007232297B2 (en) | 2006-04-03 | 2012-09-20 | Msd Italia S.R.L. | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| WO2007144637A1 (en) | 2006-06-15 | 2007-12-21 | Kudos Pharmaceuticals Limited | 2 -oxyheteroarylamide derivatives as parp inhibitors |
| WO2007144652A2 (en) | 2006-06-15 | 2007-12-21 | Kudos Pharmaceuticals Limited | Parp inhibitors |
| EP2041087A1 (en) | 2006-06-15 | 2009-04-01 | Kudos Pharmaceuticals Limited | 2 -oxybenzamide derivatives as parp inhibitors |
| WO2008015429A2 (en) | 2006-08-01 | 2008-02-07 | Sentinel Oncology Limited | Pharmaceutical compounds |
| EP2061443A4 (en) | 2006-08-18 | 2013-07-24 | Arrowhead Res Corp | POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES |
| EP1944369A1 (en) * | 2007-01-12 | 2008-07-16 | The Centre National de la Recherche Scientifique | Dbait and its standalone uses thereof |
| WO2008112193A1 (en) * | 2007-03-12 | 2008-09-18 | Dana-Farber Cancer Institute | Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents |
| WO2008146035A1 (en) | 2007-05-25 | 2008-12-04 | Astrazeneca Ab | Combination of chk and parp inhibitors for the treatment of cancers |
| CN102083314B (zh) | 2007-10-03 | 2014-04-30 | 卫材股份有限公司 | Parp抑制剂化合物、组合物以及使用方法 |
| WO2009063998A1 (ja) | 2007-11-14 | 2009-05-22 | Ribomic Inc. | 疎水性物質付加核酸及びその使用 |
| JP5788312B2 (ja) | 2008-04-11 | 2015-09-30 | アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達 |
| SA109300394B1 (ar) | 2008-06-19 | 2013-01-22 | ويث | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
| JP2012509258A (ja) | 2008-11-17 | 2012-04-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 核酸送達系のための分岐カチオン性脂質 |
| WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| EP2393364A4 (en) | 2009-02-04 | 2013-03-13 | Bipar Sciences Inc | TREATMENT OF LUNG CANCER WITH A PARP INHIBITOR IN COMBINATION WITH A GROWTH FACTOR INHIBITOR |
| DK3135301T3 (en) * | 2010-06-22 | 2018-06-25 | Onxeo | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC SUBSTANCES FOR NUCLEIC ACID CONJUGATES |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| MY166040A (en) * | 2010-09-15 | 2018-05-21 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| MX2013011932A (es) | 2011-04-11 | 2013-11-01 | Abbvie Inc | Inhibidores de parp para el tratamiento de cipn. |
| EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
| SG11201404888SA (en) | 2012-02-17 | 2014-09-26 | Pharmacyclics Inc | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
| MX2015000101A (es) * | 2012-06-27 | 2015-06-22 | Alzheimer S Inst Of America Inc | Compuestos y usos terapéuticos de los mismos. |
| US9855261B2 (en) | 2012-11-08 | 2018-01-02 | Nippon Kayaku Kabushiki Kaisha | Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same |
| CN104003979B (zh) | 2013-02-21 | 2016-08-17 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪类化合物、其药物组合物及其制备方法和用途 |
| WO2014170441A1 (en) * | 2013-04-19 | 2014-10-23 | Dna Therapeutics | Inhibition of dna damage repair by artificial activation of parp with oligonucleotide molecules |
| CN104140426B (zh) | 2013-05-07 | 2017-02-01 | 上海汇伦生命科技有限公司 | 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途 |
| CN104230896A (zh) | 2013-06-17 | 2014-12-24 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
-
2016
- 2016-07-22 AU AU2016296905A patent/AU2016296905B2/en active Active
- 2016-07-22 EP EP16744699.6A patent/EP3325623B3/en active Active
- 2016-07-22 ES ES19177392T patent/ES2879434T3/es active Active
- 2016-07-22 PL PL16744699T patent/PL3325623T6/pl unknown
- 2016-07-22 WO PCT/EP2016/067479 patent/WO2017013237A1/en not_active Ceased
- 2016-07-22 HK HK18107898.8A patent/HK1248281B/en unknown
- 2016-07-22 DK DK16744699.6T patent/DK3325623T6/da active
- 2016-07-22 PT PT16744699T patent/PT3325623T/pt unknown
- 2016-07-22 KR KR1020187005307A patent/KR101896567B1/ko active Active
- 2016-07-22 LT LT16744699T patent/LT3325623T/lt unknown
- 2016-07-22 DK DK19177392.8T patent/DK3594343T3/da active
- 2016-07-22 EP EP19177392.8A patent/EP3594343B1/en active Active
- 2016-07-22 ES ES16744699T patent/ES2742197T7/es active Active
- 2016-07-22 HU HUE16744699A patent/HUE045916T2/hu unknown
- 2016-07-22 JP JP2018502794A patent/JP6457696B2/ja active Active
- 2016-07-22 SI SI201630341T patent/SI3325623T1/sl unknown
- 2016-07-22 CA CA2993270A patent/CA2993270C/en active Active
- 2016-07-22 CN CN201680043049.2A patent/CN108138177B9/zh active Active
- 2016-07-22 US US15/746,806 patent/US10563197B2/en active Active
-
2018
- 2018-01-09 IL IL256799A patent/IL256799A/en active IP Right Grant
-
2020
- 2020-02-14 US US16/790,788 patent/US11162095B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256799A (en) | Use of a combination of dbait molecule and parp inhibitors to treat cancer | |
| IL249658A0 (en) | Methods of treating cancer using tigit inhibitors and anticancer agents | |
| IL257147B (en) | Combined treatment using liposomal irinotecan and a parp inhibitor for cancer treatment | |
| IL258900A (en) | Treatment of small cell lung cancer with a parp inhibitor | |
| IL259040B (en) | Use of toll-like receptor 8 agonists for cancer therapy | |
| IL245337A0 (en) | Combinations of checkpoint inhibitors and cancer drugs | |
| HUE071728T2 (hu) | Proliferációs betegségek kezelése Hedgehog útvonal inhibitorokat alkalmazva | |
| SG11201708153XA (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| IL254842A0 (en) | Therapeutic preparations and methods for use in cancer treatment | |
| IL266182A (en) | Farensyltransferase inhibitors for use in cancer treatment methods | |
| GB201420533D0 (en) | Use of Nanomaterials in treating cancer | |
| IL274198A (en) | Use of Nox inhibitors to treat cancer | |
| IL259781A (en) | Uses of pyrimido-pyridazinones to treat cancer | |
| SG11201605745VA (en) | Targeting clptm1l for treatment and prevention of cancer | |
| IL268722A (en) | Methods of treating cancer with farnesyl-transferase inhibitors | |
| PL3364971T3 (pl) | Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu | |
| GB201303184D0 (en) | Treatment of cancer | |
| IL272473A (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| HRP20191391T1 (hr) | Uporaba kombinacije dbait molekule i parp inhibitora za liječenje raka | |
| GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer | |
| SI3515418T1 (sl) | Uporaba zaviralcev c-MET za zdravljenje rakov, ki vsebujejo mutacije MET | |
| TWI561255B (en) | Use of umirolimus and its derivatives for treating cancer | |
| PL3010513T3 (pl) | Skojarzenie RO5503781 i kapecytabiny do leczenia raka | |
| GB201317373D0 (en) | Treatment and prevention of cancer | |
| GB201416605D0 (en) | Combination therapy to reduce the risk of and to treat cancer |